# Corcept Therapeutics Inc: financial statements, quarterly

CORT · Nasdaq · CIK 1088856 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cort.md) · [Financials](/companies/cort/financials.md) · [Filings](/companies/cort/filings.md) · [Insiders](/companies/cort/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cort/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [124](/filings/0001628280-24-044322.md) | [135 d](/filings/0001628280-26-011091.md) | [147](/filings/0001628280-25-022173.md) | [164](/filings/0001628280-25-037005.md) | [183](/filings/0001628280-25-048841.md) | [182 d](/filings/0001628280-26-011091.md) | [157](/filings/0001628280-26-028902.md) | [194](/filings/0001628280-26-050613.md) | [208](/filings/0001628280-25-048841.md) | [202 d](/filings/0001628280-26-011091.md) | [165](/filings/0001628280-26-028902.md) | [256](/filings/0001628280-26-050613.md) |
| Cost of revenue | $m | [1.6](/filings/0001628280-24-044322.md) | [1.9 d](/filings/0001628280-26-011091.md) | [2.5](/filings/0001628280-25-022173.md) | [2.5](/filings/0001628280-25-037005.md) | [2.9](/filings/0001628280-25-048841.md) | [3.0 d](/filings/0001628280-26-011091.md) | [2.4](/filings/0001628280-26-028902.md) | [3.4](/filings/0001628280-26-050613.md) | [4.6](/filings/0001628280-25-048841.md) | [2.5 d](/filings/0001628280-26-011091.md) | [2.9](/filings/0001628280-26-028902.md) | [4.1](/filings/0001628280-26-050613.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [45.5](/filings/0001628280-24-044322.md) | [54.7 d](/filings/0001628280-26-011091.md) | [58.5](/filings/0001628280-25-022173.md) | [58.7](/filings/0001628280-25-037005.md) | [59.3](/filings/0001628280-25-048841.md) | [70.3 d](/filings/0001628280-26-011091.md) | [60.7](/filings/0001628280-26-028902.md) | [60.5](/filings/0001628280-26-050613.md) | [68.8](/filings/0001628280-25-048841.md) | [64.9 d](/filings/0001628280-26-011091.md) | [66.3](/filings/0001628280-26-028902.md) | [53.9](/filings/0001628280-26-050613.md) |
| Selling, general and administrative | $m | [45.3](/filings/0001628280-24-044322.md) | [47.2 d](/filings/0001628280-26-011091.md) | [56.3](/filings/0001628280-25-022173.md) | [66.9](/filings/0001628280-25-037005.md) | [73.7](/filings/0001628280-25-048841.md) | [83.4 d](/filings/0001628280-26-011091.md) | [90.7](/filings/0001628280-26-028902.md) | [104](/filings/0001628280-26-050613.md) | [124](/filings/0001628280-25-048841.md) | [130 d](/filings/0001628280-26-011091.md) | [145](/filings/0001628280-26-028902.md) | [157](/filings/0001628280-26-050613.md) |
| Operating income | $m | [31.2](/filings/0001628280-24-044322.md) | [31.7 d](/filings/0001628280-26-011091.md) | [29.5](/filings/0001628280-25-022173.md) | [35.6](/filings/0001628280-25-037005.md) | [46.6](/filings/0001628280-25-048841.md) | [25.3 d](/filings/0001628280-26-011091.md) | [3.4](/filings/0001628280-26-028902.md) | [26.7](/filings/0001628280-26-050613.md) | [10.2](/filings/0001628280-25-048841.md) | [4.5 d](/filings/0001628280-26-011091.md) | [(49.6)](/filings/0001628280-26-028902.md) | [41.3](/filings/0001628280-26-050613.md) |
| Income tax | $m | [5.0](/filings/0001628280-24-044322.md) | [5.5 d](/filings/0001628280-26-011091.md) | [7.2](/filings/0001628280-25-022173.md) | [6.1](/filings/0001628280-25-037005.md) | [5.7](/filings/0001628280-25-048841.md) | [1.2 d](/filings/0001628280-26-011091.md) | [(10.9)](/filings/0001628280-26-028902.md) | [(3.5)](/filings/0001628280-26-050613.md) | [(4.4)](/filings/0001628280-25-048841.md) | [(14.4) d](/filings/0001628280-26-011091.md) | [(13.0)](/filings/0001628280-26-028902.md) | [2.9](/filings/0001628280-26-050613.md) |
| Net income | $m | [31.4](/filings/0001628280-24-044322.md) | [31.4 d](/filings/0001628280-26-011091.md) | [27.8](/filings/0001628280-25-048841.md) | [35.5](/filings/0001628280-25-048841.md) | [47.2](/filings/0001628280-25-048841.md) | [30.7 d](/filings/0001628280-26-011091.md) | [20.5](/filings/0001628280-26-050613.md) | [35.1](/filings/0001628280-26-050613.md) | [19.7](/filings/0001628280-25-048841.md) | [24.3 d](/filings/0001628280-26-011091.md) | [(31.8)](/filings/0001628280-26-050613.md) | [43.0](/filings/0001628280-26-050613.md) |
| Diluted EPS | $ per share | [0.28](/filings/0001628280-24-044322.md) | not reported | [0.25](/filings/0001628280-25-022173.md) | [0.32](/filings/0001628280-25-037005.md) | [0.41](/filings/0001628280-25-048841.md) | not reported | [0.17](/filings/0001628280-26-028902.md) | [0.29](/filings/0001628280-26-050613.md) | [0.16](/filings/0001628280-25-048841.md) | not reported | [(0.30)](/filings/0001628280-26-028902.md) | [0.36](/filings/0001628280-26-050613.md) |
| Basic EPS | $ per share | [0.31](/filings/0001628280-24-044322.md) | not reported | [0.27](/filings/0001628280-25-022173.md) | [0.34](/filings/0001628280-25-037005.md) | [0.45](/filings/0001628280-25-048841.md) | not reported | [0.19](/filings/0001628280-26-028902.md) | [0.33](/filings/0001628280-26-050613.md) | [0.19](/filings/0001628280-25-048841.md) | not reported | [(0.30)](/filings/0001628280-26-028902.md) | [0.40](/filings/0001628280-26-050613.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [112](/filings/0001628280-23-035988.md) | [136](/filings/0001628280-25-008167.md) | [150](/filings/0001628280-24-019610.md) | [129](/filings/0001628280-24-033284.md) | [137](/filings/0001628280-24-044322.md) | [128](/filings/0001628280-26-011091.md) | [89.8](/filings/0001628280-26-028902.md) | [103](/filings/0001628280-26-050613.md) | [125](/filings/0001628280-25-048841.md) | [120](/filings/0001628280-26-050613.md) | [109](/filings/0001628280-26-028902.md) | [111](/filings/0001628280-26-050613.md) |
| Current assets | $m | [432](/filings/0001628280-23-035988.md) | [459](/filings/0001628280-25-008167.md) | [503](/filings/0001628280-24-019610.md) | [561](/filings/0001628280-24-033284.md) | [467](/filings/0001628280-24-044322.md) | [472](/filings/0001628280-26-011091.md) | [439](/filings/0001628280-25-022173.md) | [443](/filings/0001628280-25-037005.md) | [541](/filings/0001628280-25-048841.md) | [485](/filings/0001628280-26-050613.md) | [426](/filings/0001628280-26-028902.md) | [440](/filings/0001628280-26-050613.md) |
| Total assets | $m | [594](/filings/0001628280-23-035988.md) | [622](/filings/0001628280-25-008167.md) | [656](/filings/0001628280-24-019610.md) | [715](/filings/0001628280-24-033284.md) | [784](/filings/0001628280-24-044322.md) | [841](/filings/0001628280-26-011091.md) | [846](/filings/0001628280-25-022173.md) | [802](/filings/0001628280-25-037005.md) | [824](/filings/0001628280-25-048841.md) | [837](/filings/0001628280-26-050613.md) | [815](/filings/0001628280-26-028902.md) | [889](/filings/0001628280-26-050613.md) |
| Current liabilities | $m | [122](/filings/0001628280-23-035988.md) | [105](/filings/0001628280-25-008167.md) | [97.2](/filings/0001628280-24-019610.md) | [101](/filings/0001628280-24-033284.md) | [126](/filings/0001628280-24-044322.md) | [141](/filings/0001628280-26-011091.md) | [143](/filings/0001628280-25-022173.md) | [145](/filings/0001628280-25-037005.md) | [172](/filings/0001628280-25-048841.md) | [166](/filings/0001628280-26-050613.md) | [149](/filings/0001628280-26-028902.md) | [154](/filings/0001628280-26-050613.md) |
| Total liabilities | $m | [132](/filings/0001628280-23-035988.md) | [115](/filings/0001628280-25-008167.md) | [108](/filings/0001628280-24-019610.md) | [118](/filings/0001628280-24-033284.md) | [145](/filings/0001628280-24-044322.md) | [161](/filings/0001628280-26-011091.md) | [163](/filings/0001628280-25-022173.md) | [166](/filings/0001628280-25-037005.md) | [192](/filings/0001628280-25-048841.md) | [189](/filings/0001628280-26-050613.md) | [177](/filings/0001628280-26-028902.md) | [183](/filings/0001628280-26-050613.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [462](/filings/0001628280-24-044322.md) | [507](/filings/0001628280-26-011091.md) | [548](/filings/0001628280-25-048841.md) | [596](/filings/0001628280-25-048841.md) | [639](/filings/0001628280-25-048841.md) | [680](/filings/0001628280-26-050613.md) | [683](/filings/0001628280-26-050613.md) | [636](/filings/0001628280-26-050613.md) | [632](/filings/0001628280-25-048841.md) | [648](/filings/0001628280-26-050613.md) | [638](/filings/0001628280-26-050613.md) | [706](/filings/0001628280-26-050613.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [52.9 d](/filings/0001628280-24-044322.md) | [5.5 d](/filings/0001628280-26-011091.md) | [23.8](/filings/0001628280-25-022173.md) | [41.2 d](/filings/0001628280-25-037005.md) | [73.3 d](/filings/0001628280-25-048841.md) | [60.1 d](/filings/0001628280-26-011091.md) | [4.8](/filings/0001628280-26-028902.md) | [44.3 d](/filings/0001628280-26-050613.md) | [54.5 d](/filings/0001628280-25-048841.md) | [38.4 d](/filings/0001628280-26-011091.md) | [(16.8)](/filings/0001628280-26-028902.md) | [33.5 d](/filings/0001628280-26-050613.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001628280-24-044322.md) | [0.0 d](/filings/0001628280-26-011091.md) | [0.0](/filings/0001628280-25-022173.md) | [0.4 d](/filings/0001628280-25-037005.md) | [1.6 d](/filings/0001628280-25-048841.md) | [0.1 d](/filings/0001628280-26-011091.md) | [0.1](/filings/0001628280-26-028902.md) | [0.1 d](/filings/0001628280-26-050613.md) | [0.0 d](/filings/0001628280-25-048841.md) | [0.1 d](/filings/0001628280-26-011091.md) | [0.2](/filings/0001628280-26-028902.md) | [2.5 d](/filings/0001628280-26-050613.md) |
| Share repurchases | $m | [0.0 d](/filings/0001628280-24-044322.md) | [0.0 d](/filings/0001628280-26-011091.md) | [0.5](/filings/0001628280-25-022173.md) | [3.5 d](/filings/0001628280-25-037005.md) | [11.7 d](/filings/0001628280-25-048841.md) | [0.0 d](/filings/0001628280-26-011091.md) | [27.4](/filings/0001628280-26-028902.md) | [103 d](/filings/0001628280-26-050613.md) | [42.5 d](/filings/0001628280-25-048841.md) | [0.0 d](/filings/0001628280-26-011091.md) | [0.0](/filings/0001628280-26-028902.md) | [0.0 d](/filings/0001628280-26-050613.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [117](/filings/0001628280-23-035988.md) | [115](/filings/0001628280-24-019610.md) | [110](/filings/0001628280-24-033284.md) | [111](/filings/0001628280-24-044322.md) | [110](/filings/0001628280-25-022173.md) | [111](/filings/0001628280-25-037005.md) | [114](/filings/0001628280-25-048841.md) | [120](/filings/0001628280-26-028902.md) | [120](/filings/0001628280-26-050613.md) | [119](/filings/0001628280-25-048841.md) | [104](/filings/0001628280-26-028902.md) | [118](/filings/0001628280-26-050613.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 108,098,397 at 2026-07-22, from the cover of the [10-Q filed 2026-07-29](/filings/0001628280-26-050613.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.